| Literature DB >> 29216460 |
Michael P Maher1, Jose A Matta1, Shenyan Gu1, Mark Seierstad1, David S Bredt2.
Abstract
Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, γ-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.Entities:
Keywords: AMPA receptor; GABA receptor; NMDA receptor; accessory protein; acetylcholine receptor; auxiliary subunit; drug discovery; kainite receptor; ligand-gated ion channel
Mesh:
Substances:
Year: 2017 PMID: 29216460 DOI: 10.1016/j.neuron.2017.10.001
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173